Meta-analyses evaluating the relation between poor response to clopidogrel and clinical outcome in PCI
| Meta-analyses . | Population . | Types of included studies . | No of studies/size . | Poor responders, % . | Assays . | Outcome . |
|---|---|---|---|---|---|---|
| Snoep et al49 | PCI | Any observational studies/sub-analyses of RCT | 25, n = 3688 | 21 | LTA, VASP, flow cytometry of platelet-bound fibrinogen | Composite MACE |
| OR = 8.00 (3.36-19.05) | ||||||
| Stent thrombosis | ||||||
| OR = 7.03 (0.63-79.01) | ||||||
| Clinical ischemic events | ||||||
| OR = 12.02 (5.91-24.42) | ||||||
| Sofi et al50 | PCI; 5 stable CAD-only studies | Prospective observational studies/sub-analyses of RCT | 14, n = 4564 | 26.4 | LTA, VASP, VerifyNow P2Y12 | Composite MACE |
| OR = 5.67 (2.97- 10.84) | ||||||
| Aradi et al51 | PCI; 4 stable CAD-only studies | Prospective observational studies/sub-analyses of RCT | 20, n = 9187 | 33.2 | LTA, VASP, VerifyNow P2Y12, MEA | Composite MACE |
| OR = 4.95 (3.34-7.34) | ||||||
| Stent thrombosis | ||||||
| OR = 4.14 (2.74-6.25) | ||||||
| Cardiovascular death | ||||||
| OR = 3.35 (2.39-4.70) | ||||||
| Non-fatal MI | ||||||
| OR = 3.00 (2.26-3.99) | ||||||
| Brar et al52 | PCI; 1 stable CAD-only study | Only prospective studies involving VerifyNow P2Y12 assay | 6, n = 3059 | 37.1 | VerifyNow P2Y12 assay only | For PRU cutoff >230 U |
| Individual patient data meta-analysis | Composite MACE | |||||
| HR = 2.10 (1.62-2.73) | ||||||
| Stent thrombosis | ||||||
| HR = 3.11 (1.50–6.46) | ||||||
| Death | ||||||
| HR = 1.66 (1.04-2.68) | ||||||
| Yamaguchi et al53 | PCI (98.5%) | Only prospective studies involving VerifyNow P2Y12 assay | 8, n = 4817 | 46.4 | VerifyNow P2Y12 assay only | Composite MACE |
| OR = 3.05 (2.33-3.98) | ||||||
| Stent thrombosis | ||||||
| OR = 3.26 (1.63-6.51) | ||||||
| Death | ||||||
| OR = 2.00 (1.22-3.27) |
| Meta-analyses . | Population . | Types of included studies . | No of studies/size . | Poor responders, % . | Assays . | Outcome . |
|---|---|---|---|---|---|---|
| Snoep et al49 | PCI | Any observational studies/sub-analyses of RCT | 25, n = 3688 | 21 | LTA, VASP, flow cytometry of platelet-bound fibrinogen | Composite MACE |
| OR = 8.00 (3.36-19.05) | ||||||
| Stent thrombosis | ||||||
| OR = 7.03 (0.63-79.01) | ||||||
| Clinical ischemic events | ||||||
| OR = 12.02 (5.91-24.42) | ||||||
| Sofi et al50 | PCI; 5 stable CAD-only studies | Prospective observational studies/sub-analyses of RCT | 14, n = 4564 | 26.4 | LTA, VASP, VerifyNow P2Y12 | Composite MACE |
| OR = 5.67 (2.97- 10.84) | ||||||
| Aradi et al51 | PCI; 4 stable CAD-only studies | Prospective observational studies/sub-analyses of RCT | 20, n = 9187 | 33.2 | LTA, VASP, VerifyNow P2Y12, MEA | Composite MACE |
| OR = 4.95 (3.34-7.34) | ||||||
| Stent thrombosis | ||||||
| OR = 4.14 (2.74-6.25) | ||||||
| Cardiovascular death | ||||||
| OR = 3.35 (2.39-4.70) | ||||||
| Non-fatal MI | ||||||
| OR = 3.00 (2.26-3.99) | ||||||
| Brar et al52 | PCI; 1 stable CAD-only study | Only prospective studies involving VerifyNow P2Y12 assay | 6, n = 3059 | 37.1 | VerifyNow P2Y12 assay only | For PRU cutoff >230 U |
| Individual patient data meta-analysis | Composite MACE | |||||
| HR = 2.10 (1.62-2.73) | ||||||
| Stent thrombosis | ||||||
| HR = 3.11 (1.50–6.46) | ||||||
| Death | ||||||
| HR = 1.66 (1.04-2.68) | ||||||
| Yamaguchi et al53 | PCI (98.5%) | Only prospective studies involving VerifyNow P2Y12 assay | 8, n = 4817 | 46.4 | VerifyNow P2Y12 assay only | Composite MACE |
| OR = 3.05 (2.33-3.98) | ||||||
| Stent thrombosis | ||||||
| OR = 3.26 (1.63-6.51) | ||||||
| Death | ||||||
| OR = 2.00 (1.22-3.27) |